Literature DB >> 11160203

Role of phosphatidylinositol 3-kinase in anti-IgM- and anti-IgD-induced apoptosis in B cell lymphomas.

G B Carey1, D W Scott.   

Abstract

Cross-linking of surface Ig receptors with anti IgM (anti-mu heavy chain, anti-mu), but not anti-IgD (anti-delta heavy chain, anti-delta), Abs leads to growth arrest and apoptosis in several extensively characterized B cell lymphomas. By poorly understood mechanisms, both Igs transiently stimulate c-Myc protein expression. However, ultimately, only anti-mu causes a severe loss in c-Myc and a large induction of p27(Kip1) protein expression. Because phosphatidylinositol 3-kinase (PI3K) has been established as a major modulator of cellular growth and survival, we investigated its role in mediating anti-Ig-stimulated outcomes. Herein, we show that PI3K pathways regulate cell cycle progression and apoptosis in the ECH408 B cell lymphoma. Anti-mu and anti-delta driven c-Myc protein changes precisely follow their effects on the PI3K effector, p70(S6K). Upstream of p70(S6K), signaling through both Ig receptors depresses PI3K pathway phospholipids below control with time, which is followed by p27(Kip1) induction. Conversely, anti-delta, but not anti-mu stimulated PI3K-dependent phospholipid return to control levels by 4-8 h. Abrogation of the PI3K pathway with specific inhibitors mimics anti-mu action, potentiates anti-mu-induced cell death and, importantly, converts anti-delta to a death signal. Transfection with active PI3K kinase construct induces anti-mu resistance, whereas transfection with dominant negative PI3K augments anti-mu sensitivity. Our results show that prolonged disengagement of PI3K or down-regulation of its products by anti-mu (and not anti-delta) determines B cell fate.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160203     DOI: 10.4049/jimmunol.166.3.1618

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  A differential requirement for phosphoinositide 3-kinase reveals two pathways for inducible upregulation of major histocompatibility complex class II molecules and CD86 expression by murine B lymphocytes.

Authors:  Stuart Marshall-Clarke; Lynn Tasker; Mark P Heaton; R Michael E Parkhouse
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

2.  hIgD promotes human Burkitt lymphoma Daudi cell proliferation by accelerated G1/S transition via IgD receptor activity.

Authors:  Xing Dai; YuJing Wu; XiaoYi Jia; Yan Chang; HuaXun Wu; Chun Wang; HengShi Chen; WenSheng Chen; Qiong Huang; Wei Wei
Journal:  Immunol Res       Date:  2016-08       Impact factor: 2.829

3.  Pivotal advance: CEACAM1 is a negative coreceptor for the B cell receptor and promotes CD19-mediated adhesion of B cells in a PI3K-dependent manner.

Authors:  Elizabeth O Lobo; Zhifang Zhang; John E Shively
Journal:  J Leukoc Biol       Date:  2009-05-19       Impact factor: 4.962

4.  PU.1 regulates positive regulatory domain I-binding factor 1/Blimp-1 transcription in lymphoma cells.

Authors:  Shruti Desai; Sophia C E Bolick; Michelle Maurin; Kenneth L Wright
Journal:  J Immunol       Date:  2009-10-14       Impact factor: 5.422

5.  CTCF functions as a critical regulator of cell-cycle arrest and death after ligation of the B cell receptor on immature B cells.

Authors:  Chen-Feng Qi; Annica Martensson; Michela Mattioli; Riccardo Dalla-Favera; Victor V Lobanenkov; Herbert C Morse
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-10       Impact factor: 11.205

6.  Overexpression of miR-199a-5p decreases esophageal cancer cell proliferation through repression of mitogen-activated protein kinase kinase kinase-11 (MAP3K11).

Authors:  Kimberly A Byrnes; Pornima Phatak; Daniel Mansour; Lan Xiao; Tongtong Zou; Jaladanki N Rao; Douglas J Turner; Jian-Ying Wang; James M Donahue
Journal:  Oncotarget       Date:  2016-02-23

7.  Thy28 partially prevents apoptosis induction following engagement of membrane immunoglobulin in WEHI-231 B lymphoma cells.

Authors:  Hiroko Toyota; Xiao-Zhou Jiang; Hideki Asakura; Junichiro Mizuguchi
Journal:  Cell Mol Biol Lett       Date:  2011-12-02       Impact factor: 5.787

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.